Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo
| Autor: | Andrew P. Mazar, Teresa K. Woodruff, Marcel B. Bally, Lidia Spaho, Meera R. Raja, Leo I. Gordon, Michael J. Avram, Richard W. Ahn, Lonnie D. Shea, Jane N. Winter, Thomas V. O'Halloran, Susan L. Barrett, Haimei Chen, Jennifer K. Jozefik |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Lymphoma
Cancer Treatment lcsh:Medicine Pharmacology Arsenicals Hematologic Cancers and Related Disorders chemistry.chemical_compound Mice 0302 clinical medicine Arsenic Trioxide Ovarian Follicle Drug Discovery Nanotechnology Arsenic trioxide lcsh:Science media_common 0303 health sciences Multidisciplinary Obstetrics and Gynecology Oxides Hematology 3. Good health medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Medicine Lymphomas Female Research Article Biotechnology Drug media_common.quotation_subject Materials Science Ovary Antineoplastic Agents Biology 03 medical and health sciences Nanocapsules In vivo Cell Line Tumor medicine Animals Humans Ovarian follicle Ovarian reserve 030304 developmental biology Nanomaterials lcsh:R Cancer Chemotherapy and Drug Treatment medicine.disease Female Subfertility Xenograft Model Antitumor Assays Fertility chemistry Bionanotechnology Cancer research lcsh:Q |
| Zdroj: | PLoS ONE PLoS ONE, Vol 8, Iss 3, p e58491 (2013) |
| ISSN: | 1932-6203 |
| Popis: | Advances in cancer therapy have increased the rate of survival of young cancer patients; however, female lymphoma patients frequently face a temporary or permanent loss of fertility when treated with traditional cytotoxic agents. The potential loss of fertility is an important concern that can influence treatment decisions for many premenopausal cancer patients. The negative effect of chemotherapeutic agents and treatment protocols to patients’ fertility–referred to as fertotoxicity–are thus an increasingly important cancer survivorship issue. We have developed a novel nanoscale formulation of arsenic trioxide, a potent drug for treatment of hematological malignancies, and demonstrate that it has significantly better activity in a murine lymphoma model than the free drug. In parallel, we have developed a novel in vitro assay of ovarian follicle function that predicts in vivo ovarian toxicity of therapeutic agents. Our results reveal that the nanotherapeutic agent is not only more active against lymphoma, but is fertoprotective, i.e., it is much less deleterious to ovarian function than the parent drug. Thus, our in vitro assay allows rapid evaluation of both established and experimental anticancer drugs on ovarian reserve and can inform the selection of efficacious and fertility-sparing treatment regimens for reproductive-age women diagnosed with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|